Literature DB >> 16696962

Plasma markers of activated hemostasis in the early diagnosis of acute coronary syndromes.

Roy F M van der Putten1, Jan F C Glatz, Wim Th Hermens.   

Abstract

BACKGROUND: Because acute coronary syndromes (ACS) are caused by intracoronary thrombosis, plasma markers of coagulation have relevance for early diagnosis. AIMS AND
OBJECTIVES: To provide a critical review of these studies and specific attempts to close the diagnostic time gap left by traditional plasma markers of heart injury.
METHODS: Studies of ACS patients, with at least one control group, were included when blood samples were taken within 24 h after first symptoms prior to medication or intervention. Special attention was paid to studies reporting diagnostic performance, or combination of several markers into a single diagnostic index.
RESULTS: Markers with short plasma half-life (FPA, TAT, etc.) reflect ongoing thrombosis and may identify patients at increased risk. Markers with longer half-life (F1+2, D-Dimer, etc.) may be more useful to indicate a single acute thrombotic event. However, results are highly variable and depend on sampling time, clot property, degree of coronary obstruction and physiological condition. Early diagnostic performance of hemostatic markers was poor even when combined with heart injury markers.
CONCLUSIONS: Early measurement of hemostatic plasma markers in ACS patients provides pathophysiological information and may be helpful in risk stratification or to monitor anticoagulant therapy, but does not seem useful in routine clinical diagnosis of ACS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16696962     DOI: 10.1016/j.cca.2006.03.005

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

Review 1.  New methods for improved evaluation of patients with suspected acute coronary syndrome in the emergency department.

Authors:  U Ekelund; J L Forberg
Journal:  Emerg Med J       Date:  2007-12       Impact factor: 2.740

2.  A study of atherothrombotic biomarkers in welders.

Authors:  Dag G Ellingsen; Maxim Chashchin; Ingebjørg Seljeflot; Balazs Berlinger; Valery Chashchin; Leo Stockfelt; Yngvar Thomassen
Journal:  Int Arch Occup Environ Health       Date:  2019-05-21       Impact factor: 3.015

3.  Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.

Authors:  Carey Kimmelstiel; Ping Zhang; Navin K Kapur; Andrew Weintraub; Barath Krishnamurthy; Vilma Castaneda; Lidija Covic; Athan Kuliopulos
Journal:  Circ Cardiovasc Interv       Date:  2011-03-01       Impact factor: 6.546

4.  Prognostic value of D-dimer and markers of coagulation for stratification of abdominal aortic aneurysm growth.

Authors:  Alexandra C Sundermann; Keith Saum; Kelsey A Conrad; Hannah M Russell; Todd L Edwards; Kevin Mani; Martin Björck; Anders Wanhainen; A Phillip Owens
Journal:  Blood Adv       Date:  2018-11-27

5.  Elevated levels of soluble fibrin in patients with venous thromboembolism.

Authors:  Akihiro Tsuji; Hideo Wada; Takeshi Matsumoto; Yasunori Abe; Satoshi Ota; Norikazu Yamada; Takashi Sugiyama; Akihiro Sudo; Katsuya Onishi; Kaname Nakatani; Atsumasa Uchida; Masaaki Ito; Koji Suzuki; Tsutomu Nobori
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

6.  Diagnostic value of D-dimer measurement in patients referred to the emergency department with suspected myocardial ischemia.

Authors:  Giuseppe Lippi; Luca Filippozzi; Martina Montagnana; Gian Luca Salvagno; Gian Cesare Guidi
Journal:  J Thromb Thrombolysis       Date:  2007-06-01       Impact factor: 2.300

7.  Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events.

Authors:  Rinske Loeffen; René van Oerle; Mathie P G Leers; Johannes A Kragten; Harry Crijns; Henri M H Spronk; Hugo Ten Cate
Journal:  PLoS One       Date:  2016-07-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.